← All Atyr Pharma INC filings

Atyr Pharma INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
ATYR
Atyr Pharma INC
10-Q: aTyr Pharma's Lead Drug Misses Primary Endpoint in Phase 3 Sarcoidosis Trial
aTyr Pharma reported a net loss of $25.7 million for Q3 2025 and announced its lead therapeutic candidate, efzofitimod, failed to meet its primary endpoint in a pivotal Phase 3 pulmonary sarcoidosis study.
NASDAQ
ATYR
Atyr Pharma INC
10-Q: aTyr Pharma Advances Efzofitimod, Faces Manufacturing Hurdles
aTyr Pharma reports progress in its clinical trials for efzofitimod, with Phase 3 data expected in September 2025, but notes manufacturing deviations and continued net losses.
NASDAQ
ATYR
Atyr Pharma INC
10-Q: aTyr Pharma Reports Q1 2025 Financial Results, Provides Clinical Program Update
aTyr Pharma reports its Q1 2025 financial results, highlighting ongoing clinical trials for efzofitimod and providing an update on its financial condition.
NASDAQ
ATYR
Atyr Pharma INC
10-Q: aTyr Pharma Reports Q3 2024 Results, Provides Update on Clinical Programs
aTyr Pharma's Q3 2024 report details financial results and progress in clinical trials, including the EFZO-FIT study for pulmonary sarcoidosis and the EFZO-CONNECT study for SSc-ILD.
NASDAQ
ATYR
Atyr Pharma INC
10-Q: aTyr Pharma Reports Q2 2024 Results, Exceeds Enrollment Target for Sarcoidosis Trial
aTyr Pharma's Q2 2024 report shows increased R&D spending, completion of enrollment for the EFZO-FIT study, and a net loss of $16.3 million.
NASDAQ
ATYR
Atyr Pharma INC
10-Q: aTyr Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
aTyr Pharma's first quarter 2024 results show a net loss of $15.5 million, with ongoing clinical trial expenses and preparation for a potential biologics license application.